Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osimertinib Rechallenge after Osimertinib-Associated ILD in EGFR-Mutated Advanced NSCLC (CRETE)
jRCT1030240645Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Apr 2025
- Modality
- Small Molecules
01
Overview
Open-label, single-arm trial of osimertinib in EGFR-mutated non-small cell lung cancer, sponsored by AstraZeneca. Primary endpoint: Proportion of patients rechallenged after ILD. Started Apr 2025; status: active, not recruiting.
02
Drugs
03
Conditions
EGFR-mutated non-small cell lung cancer
Beyond the preview
Go deeper on jRCT1030240645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1030240645.